How do these insider transactions compare to those of previous quarters or years?

Answer

The announcement you’ve shared tells us what insider‑related transactions occurred in Novo Nordisk A/S (ticker NVO) during the reporting period that ends on 7 August 2025. However, the release does not include any figures or details from earlier quarters or years, so a direct, data‑driven comparison cannot be made from the information provided alone.

Below is a step‑by‑step outline of what a full comparison would normally involve, together with the specific gaps we face in this case and suggestions on how you can obtain the missing historical data.

1. What the current announcement typically contains

Regulation No 596/2014 (Market Abuse Regulation) requires insiders to disclose:

Your excerpt only tells us that some transactions were disclosed on 7 Aug 2025; the actual tables with the above details are not included in the snippet you posted.

2. How a historical comparison is usually built

A. Key metrics to track over time

1. Transaction volume – total number of shares bought vs. sold each quarter.
2. Monetary value – total cash amount of purchases and sales.
3. Net buying/selling – the difference between purchases and sales (e.g., “net bought 1.2 M shares, net sold 0.3 M shares”).
4. Frequency of trades – number of distinct insider trades per reporting period.
5. Insider concentration – which specific insiders are most active (e.g., CEO vs. CFO vs. board members).
6. Directionality – proportion of insiders buying versus selling (a higher proportion of buying can be interpreted as confidence in the company’s outlook, while predominant selling may raise questions).

B. Typical sources for historic insider data

• Novo Nordisk’s own investor‑relations website – they archive past “Insider Transaction” releases (often quarterly).
• Regulatory filings – the Danish Financial Supervisory Authority (Finanstilsynet) or the EU’s Transparency Register host historic disclosures.
• Commercial data providers – Bloomberg, Refinitiv, FactSet, or Thomson Reuters track insider trades and can generate time‑series reports.
• Public databases – websites such as OpenInsider, InsiderMonitor, or SEC’s EDGAR (for U.S.-listed ADRs) often compile historic insider activity.

C. Analytical approach

1. Collect quarterly data for the past 4‑8 quarters (or the last 2‑3 years) from the sources above.
2. Standardise the figures (e.g., convert all values to USD or EUR, adjust for stock splits, etc.).
3. Create a time‑series table:

1. Visualise the trends (e.g., bar chart of net shares bought per quarter, line chart of total insider‑trade value).
2. Interpret any notable shifts:
   • Spike in buying → could signal insider confidence, perhaps linked to a new product launch or favorable earnings outlook.
   • Spike in selling → might be driven by personal liquidity needs, tax planning, or a perception of overvaluation.
   • Consistent net buying over multiple quarters → often viewed positively by analysts.

3. What we can say right now based on the limited information

4. How to obtain the missing historical data

1. Visit Novo Nordisk’s Investor Relations portal – look for a “Regulation 19 disclosures” or “Insider transactions” archive.
   
2. Search the EU’s ESMA MARS (Market Abuse Regulation System) database – you can filter by issuer (NVO) and date range.
   
3. Use a financial‑data platform (e.g., Bloomberg INSIDER function) and pull a “historical insider trade” report for Novo Nordisk.
   
4. If you have a subscription to a newswire (e.g., GlobeNewswire) – request the full press release for 7 Aug 2025; it will contain the detailed tables that can be saved and compared against earlier releases.

5. Suggested next steps for a complete answer

1. Gather the past releases (e.g., Q1 2024, Q2 2024, Q3 2024, Q4 2024, Q1 2025, Q2 2025).
   
2. Extract the key figures (shares bought/sold, values, net positions).
   
3. Populate a comparative table as shown in Section 2C.
   
4. Add a brief commentary highlighting any trends (e.g., “Insider net buying has risen from a net sell of 0.4 M shares in Q2 2024 to a net buy of 1.1 M shares in Q3 2025, representing a 175 % swing.”).
   
5. Include visual aids (charts/graphs) for quick insight.

Bottom line

• From the current news alone: We only know that insider transactions were disclosed for the period ending 7 Aug 2025.
  
• To compare with previous quarters/years: You’ll need to retrieve historic insider‑transaction filings (via Novo Nordisk’s website, regulatory portals, or data‑vendor services) and then perform a side‑by‑side analysis of volume, value, and net direction.
  

Once you have those historic figures, you can apply the framework above to produce a comprehensive, data‑driven comparison. If you’d like, I can walk you through how to pull the data from a specific source (e.g., Bloomberg, the EU Transparency Register) or help you design the comparison table once the numbers are in hand.